TY - JOUR
T1 - Criteria for preclinical models of cholangiocarcinoma
T2 - scientific and medical relevance
AU - CCA Model Consortium
AU - Calvisi, Diego F.
AU - Boulter, Luke
AU - Vaquero, Javier
AU - Saborowski, Anna
AU - Fabris, Luca
AU - Rodrigues, Pedro M.
AU - Coulouarn, Cédric
AU - Castro, Rui E.
AU - Segatto, Oreste
AU - Raggi, Chiara
AU - van der Laan, Luc J.W.
AU - Carpino, Guido
AU - Goeppert, Benjamin
AU - Roessler, Stephanie
AU - Kendall, Timothy J.
AU - Evert, Matthias
AU - Gonzalez-Sanchez, Ester
AU - Valle, Juan W.
AU - Vogel, Arndt
AU - Bridgewater, John
AU - Borad, Mitesh J.
AU - Gores, Gregory J.
AU - Roberts, Lewis R.
AU - Marin, Jose J.G.
AU - Andersen, Jesper B.
AU - Alvaro, Domenico
AU - Forner, Alejandro
AU - Banales, Jesus M.
AU - Cardinale, Vincenzo
AU - Macias, Rocio I.R.
AU - Vicent, Silve
AU - Chen, Xin
AU - Braconi, Chiara
AU - Verstegen, Monique M.A.
AU - Fouassier, Laura
AU - Scheiter, Alexander
AU - Selaru, Florin M.
AU - Evert, Katja
AU - Utpatel, Kirsten
AU - Broutier, Laura
AU - Cadamuro, Massimiliano
AU - Huch, Meritxell
AU - Goldin, Robert
AU - Gradilone, Sergio A.
AU - Saito, Yoshimasa
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/7
Y1 - 2023/7
N2 - Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.
AB - Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.
UR - http://www.scopus.com/inward/record.url?scp=85147649578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147649578&partnerID=8YFLogxK
U2 - 10.1038/s41575-022-00739-y
DO - 10.1038/s41575-022-00739-y
M3 - Article
C2 - 36755084
AN - SCOPUS:85147649578
SN - 1759-5045
VL - 20
SP - 462
EP - 480
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
IS - 7
ER -